Etibant is a potent selective bradykinin B2 receptor and antagonist. Etibant inhibits the local swelling of acute HAE thromboembolism by inhibiting the effects of bradykinin related to local swelling, inflammation and pain symptoms. For the treatment of hereditary angioedema (HAE) in adults aged 18 and over.